Trulieve Cannabis Corp. (TSE:TRU – Free Report) – Research analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Trulieve Cannabis in a report released on Monday, March 3rd. Roth Capital analyst W. Kirk expects that the company will post earnings of ($0.13) per share for the quarter. Roth Capital also issued estimates for Trulieve Cannabis’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.10) EPS and FY2026 earnings at ($0.33) EPS.
Other equities research analysts also recently issued reports about the stock. Atb Cap Markets raised shares of Trulieve Cannabis from a “hold” rating to a “strong-buy” rating in a report on Monday, December 9th. Craig Hallum upgraded Trulieve Cannabis to a “strong-buy” rating in a research report on Wednesday, February 26th.
Trulieve Cannabis Stock Performance
Insider Activity
In related news, Senior Officer Wes Getman acquired 9,500 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of C$7.02 per share, for a total transaction of C$66,702.35.
Trulieve Cannabis Company Profile
TransUnion provides risk and information solutions. The company operates in three segments: U.S. Markets, International, and Consumer Interactive. The U.S. Markets segment provides consumer reports, actionable insights, and analytics to businesses. These businesses use its services to acquire new customers; assess consumer ability to pay for services; identify cross-selling opportunities; measure and manage debt portfolio risk; collect debt; verify consumer identities; and mitigate fraud risk.
Recommended Stories
- Five stocks we like better than Trulieve Cannabis
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Okta’s Stock Reversal Gains Momentum—20% Upside Ahead
- What is the Shanghai Stock Exchange Composite Index?
- Tariffs Won’t Stop These 3 Stocks From Rising
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Missed the Hims & Hers Rally? Clover Health Could Be Next
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.